Pharmamarketeer

OxThera gets positive opinion from EMA on PIP for treatment of primary hyperoxaluria with Oxalobacter formigenes

OxThera AB, a privately─held biopharmaceutical company dedicated to improving the lives of people with primary hyperoxaluria (PH), announced that, based on a positive opinion from the Paediatric

Medhc-fases-banner
Advertentie(s)